STOCKS TELEGRAPH

Author: Mustafa Bin Tariq

  • Renewable Energy Group Inc (REGI) stock is rising in pre-market. Here’s why

    The stock of Renewable Energy Group (REGI) gained 15.08% in the pre-market to $37.54. REGI stock closed the regular trading session at $32.62, 2.34% less than the previous trading session. The gain came after the news by the company about reporting the earnings for Q4 of FY21.

    Renewable Energy Group (REGI) biodiesel manufacturing organization. The company looks up to 12 biorefineries and feedstock offices. REGI has a market capitalization of $1.64 billion with 50.27 million outstanding shares. The company has its headquarter in Ames, Iowa, United States of America (USA).

    REGI News

    The company on 18 February 2022, notified the prudent collaboration with Bunker Holdings to additionally foster the U.S. also EU marine business sectors for practical biodiesel. This collaboration will permit the organizations to assume an explanatory part in changing the transit business to new and more durable energy sources.

    The senior vice president of REGI, Bob Kenyon, stated that at REGI they see a chance for biodiesel to be a durable fuel choice for clients in the perfect energy-changing environment. He further stated that cooperating with Bunker Holding will speed up the marine business adaption of biodiesel. Moreover, Mr. Kenyon concluded that they anticipate fostering their relationship with Bunker Holding and supporting the transit business decarbonization development.

    In addition, Renewable Energy Group, on 17 February 2022, declared a well-thought-out investment. The company will introduce a treatment plant in Germany. This plant will refine the least carbon force, hardest to change fats and oils for biodiesel creation. Not only but also, this venture will improve REGI capacity to create renewable fuel from a more extensive assortment of feedstocks. The CEO of REGI, CJ Warner, communicated that this investment qualifies them to exceedingly serve the developing interest for low carbon fuel choices in Europe.

    What next

    On 22 February 2022, REGI declared the release of its Q4 financial results for the fiscal year 2021. The results will be released before the opening of the market on 1 March 2022.

  • Revelation Biosciences, Inc. (REVB) stock gained 64.29% in the pre-market. Here’s why

    Revelation Biosciences, Inc. (REVB) stock gained 64.29% in the pre-market. Here’s why

    The stock of Revelation Biosciences Inc (REVB) closed the recent trading session at $1.54, gaining 4.76% from the previous trading session. The stock remained bullish in the pre-market and gained 64.29% to $2.53. The company filed for the form SC 13D with the SEC on 15 February 2022. The form refers to the acquisition of the beneficial owner of more than 5% securities.

    REVB News:

    On 24 January 2022, REVB declared the selling of 1.29 million stocks at a cost of $3 for each stock. Moreover, the company also proceeded with 1.29 million warrants. The price of warrants is $3.29 each, which will be exercisable within the 6 months of issuance. The expiry date will be after five and a half years from the date of issue. The aggregate amount will be almost $7.7 million. REVB will use the amount from the offering in clinical and pre-clinical trials.

    Also, on 20 January 2022, the company reported that a class of at least 15 patients have been selected and dosed in a Phase 2b viral test review. The trials were conducted to assess the viability of intranasal REVTx-99 for the therapy of H3N2 flu. The test review is an important stage in the clinical advancement of REVTx-99 for the treatment of respiratory diseases.

    The CEO of REVB, James Rolke, stated that with the rise in diseases like flu, and COVID-19, there is a colossal requirement for new treatments. He further stated that the consequences of this study will be a sign of the improvement of REVTx-99. Mr. Rolke concluded that despite having antibodies, there stays an earnest requirement for the treatment of respiratory viral contaminations.

    What’s next

    REVB further focuses on the evolution of clinical investigation related to COVID-19 and its different adaptions. The company also plans to continue investigation related to other respiratory diseases.

    About REVB

    Revelation Biosciences Inc is a clinical-stage pharmaceutical organization that concentrates on the production of immune system therapies. The company has its headquarter in California, the United States of America (USA).

  • Virgin Galactic Holdings Inc (SPCE) stock is gaining in the pre-market. Here’s why

    The stock of Virgin Galactic Holding Inc (SPCE) closed the regular trading session at $7.82. SPCE stock lost 6.9% from the previous trading session. The stock gained 3.84% in the pre-market, to $8.12. Virgin Galactic share kept moving between $7.71 and $8.27 during the regular trading session. The company released the results for the fourth financial quarter of fiscal year 2021. SPCE also filed form 8-K with the SEC on February 22, 2022, to report the quarterly earnings.

    Virgin Galactic Holdings Inc is an aviation organization. The company is centered around the development, manufacturing and activities of spaceships.

    Q4 2021 of SPCE

    On February 22, 2022, SPCE released the results of the fourth financial quarter of fiscal year 2021, that ended on December 31, 2021. The key financial highlights of the company are

    • SPCE had a revenue of $0.14 million in the Q4 of financial year 2021.
    • The company posted a net loss of $80.7 million in Q4 of FY21 versus $104.1 million in the year ago quarter. Net loss decreased by 22.4%.
    • Diluted loss of $0.31 per share in Q4 for fiscal year 2021 as compared to $0.44 in Q4 of FY20.
    • Furthermore, adjusted EBITDA loss was $64.8 million in Q2 of FY21 versus $59.5 in the same quarter last year.

    Virgin Galactic opened sales for the private astronauts at a new price of $0.45 million. The company also launched new headquarters for engineering and design. Also, SPCE launched a corporate headquarter. Virgin Galactic also completed its first spaceflight from New Mexico. In addition, it unfolded the Spaceship III, which is the second spaceship in the fleet.

    SPCE predicted a free cash flow between $75 to $85 million for the Q1 of fiscal year 2022.

    CEO Remarks

    The CEO of Virgin Galactic Holding (SPCE), Michael Colglaziar, said that stay on the target of their enhancement program. They are also focused on the inauguration of commercial services in the current year. He further said that they accomplished numerous significant achievements in 2021.

    Furthermore, Mr Colglaziar said that as of now they are working on their operations to fit in with the customer growth.

  • Esports Entertainment Group Inc (GMBL) stock lost 31.31% in the after-market. Here’s why

    Esports Entertainment Group Inc (GMBL) stock lost 31.31% in the after-market. Here’s why

    The stock of Esports Entertainment Group Inc (GMBL) closed the recent trading session at $2.97. The stock lost 8.62% from the previous trading session. During the last check, the stock of GMBL nosedived in the after-market, losing 31.31% to $2.04. Esports Entertainment announced the financial results for the second quarter of 2022. The company also filed forms 10-Q and 8-K with the SEC on February 22, 2022. These forms refer to the report of the quarterly earnings.

    Esports Entertainment Group Inc is an e-sports and online gambling platform. The company operates by the development of video gaming and the ascendance of esports. The esports games of the company include Dota 2, Fortnite, Counter-Strike, and more. As of now, the market capitalization of GMBL is $66.50 million, with 22.39 million outstanding shares.

    GMBL Quarterly Outlook:

    On February 22, 2022, GMBL announced the financial results of the second quarter of the fiscal year 2022, which ended on December 31, 2021. According to the results, the revenue of GMBL increased by 515%. The company posted revenue of $14.5 million in Q2 of FY22, an increase of $12.1 million from the year-ago quarter. The net loss was $34.3 million in the second quarter of FY22 versus $7.2 million in the same quarter of the previous year. Net loss of the company increased by 370%. The company had a loss per share of $1.53 in Q2 of FY22 as compared to $0.57 in Q2 of the fiscal year 2021. Moreover, the total loss to the adjusted EBITDA in Q2 of the financial year 2022 was $6.7 million versus $3.8 million in Q2 of the financial year 2021.

    GMBL effectively finished the relocation of its SportNation.com and Vie. bet iGaming destinations to its restrictive Idefix platform. An announcement was also made about the renewal of the partnership with the NBA 2K league in January 2022. OMEGA platform was also released by the company. OMEGA enables the businesses like the offering of esports by movie theaters, shopping malls, and family centers.

    Management Remarks:

    The CEO of GMBL, Grant Johnson, said that the results of the second quarter depict various challenges for them. He further said that they remain bullish about reaching the annual revenue of $100 million in the preceding year.

    Moreover, Mr. Johnson said that they believe their future is bright with the new products and the strength of their European-based iGaming and online sports betting platform.

  • Phunware Inc (PHUN) stock is gaining in the pre-market. Here’s why

    The stock of Phunware Inc (PHUN) closed the recent trading session at $3.18, losing 3.05% from the previous trading session. The stock surged in the pre-market, gaining 13.52% to $3.61. PHUN filed the form SC 13G/A with the SEC on February 14, 2022. The form refers to the acquisition of beneficial ownership of 5% or more of equity securities. The company also announced the PhunToken uniswap liquidity pool rewards program.

    News

    On February 17, 2022, Phunware Inc (PHUN) announced the launch of PhunToken (PTHK) liquidity swap rewards for a trading pair of Ether-PhunToken. The program will be launched at Uniswap V2. Besides, the PTHK is currently available on the Phuntoken website for purchase against BTC, US Dollar, or ETH.

    The reward program will release next month. The eligible wallets will get the first reward in April. The entitled providers will get the rewards for at least a 30-day period. These rewards are apart from the 0.3% fee that the providers get from the Uniswap trades.

    The CEO of PHUN, Alan S. Knitowski, said that they are excited to make this significant next stride in commercializing a genuinely decentralized data economy. This can use the features and abilities of their Multiscreen-as-a-Service (MaaS) stage. He further added that exchanges like Uniswap will help them in decentralizing the PhunToken and will stretch out admittance to MaaS usefulness, globally.

    Moreover, the eligibility criteria for PhunToken are that members should effectively finish the KYC/AML process. Further, each liquidity is expectable for the reward after 30 days of addition. Not only also, but all members will also split the reward pool. If ETH-PHTK liquidity is taken out anytime, all past liquidity for that lock period will be excluded.

    About PHUN

    Phunware Inc (PHUN) participates in the development of a Multiscreen-as-a-Service platform (MaaS) for mobile. In addition, the products and services include mobile software licenses in software development kits (SDKs) form utilized inside mobile applications. The company has its headquarter in Austin, Texas, United States of America (USA).

     

     

  • AdvanSix Inc. (ASIX) stock gained in the after-market. Here’s why

    The stock of AdvanSix Inc (ASIX) closed the recent trading session at $34.2. The stock lost 16.91% as compared to the previous trading session. During the last check, ASIX surged in the after-market, gaining 20.35% to $41.16. The company announced the financial results for the fourth quarter and full year of the fiscal year 2021. AdvanSix also filed for the Form 10-K and 8-K with the SEC on February 18, 2022. These forms were filed to report the quarterly and full-year earnings.

    ASIX Financials

    On February 18, 2022, AdvanSix Inc (ASIX) announced the financial results for the fourth quarter and full year of the fiscal year 2021. The main highlights of the financial results are

    • ASIX posted sales of $424.06 million in Q4 of FY21 as compared to $340.2 million in the year-ago quarter. The full-year sales of the company were $1.6 billion in FY21 against $1.1 billion in FY20. The sales saw an increase of 24.6% and 45.4%, respectively.
    • Net income for Q4 of FY21 was $23.5 million versus $26.7 million in Q4 of FY20. The full-year net income for 2021 was $139.7 million versus $46.07 million in 2020. The net income increased by -0.11% and 203.2%, respectively.
    • Diluted EPS was $0.80 in the fourth quarter of FY21 as compared to $0.94 in the same quarter of FY20.
    • The EBITDA of ASIX for the fourth quarter of FY21 was $49.2 million against $48.6 million in Q4 of FY20.

    CEO Remarks

    The CEO of AdvanSix (ASIX), Erin Kane, said that in 2021, they delivered outstanding results while navigating the COVID-19 pandemic, supply chain disruptions, and inflation. He further added that they achieved a record annual EBITDA and free cash flow, executed their first acquisition and reduced their debt.

    Moreover, Mr. Kane said that their strong results indicate their resilience, strength, and leadership across their diversified portfolio.

  • HOOKIPA Pharma Inc. (HOOK) stock is gaining in after-hours. Here’s why

    The stock of HOOKIPA Pharma Inc (HOOK) closed the recent trading session at $2.48, gaining 24% from the previous trading session. The stock of HOOK further gained 9.27% to $2.71, in the after-hours. The company announced the collaboration with Gilead to develop immunotherapies against HIV. HOOK also filed for the form SC 13G/A and 3 with the SEC, on February 17, 2022.

    News

    On February 15, 2022, HOOKIPA Pharma made an announcement regarding the collaboration and license agreement with Gilead. According to the agreement, HOOK and Gilead will work on developing the treatment for the human immunodeficiency virus (HIV). Also, Gilead licensed the exclusive rights to HOOKIPA’s arenaviral platform to develop treatments for HIV and hepatitis B.

    Moreover, given the terms and conditions, HOOPIKA will be responsible for the completion of Phase 1b clinical trials. The funding will be provided by Gilead. The total funding agreement is $50 million. The terms include $15 million as an upfront payment and $35 million as an equity purchase. In addition, the exclusive rights for further development will be given to Gilead after the completion of clinical trials. HOOK filed for form 8-K with the SEC on February 15, 2022. The filing of Form 8-K holds the details of the agreement.

    The CEO of HOOKIPA Pharma, Joern Aldag, said that they are happy to enter this agreement with Gilead. He further added that this agreement will help both parties and the HIV community. Moreover, he said that Gilead is helping them in advancing their arenaviral platform technology.

    About HOOK

    HOOKIPA Pharma Inc is a clinical-stage pharmaceutical company that focuses on creating novel treatments. The novel treatment prepares and enhances designated T cells to address neglected requirements in cancer. HOOKIPA’s pipeline incorporates investigational arenaviral therapies focusing on Human Papilloma Virus 16-positive malignant growths, prostate cancer, KRAS-changed tumor, and other undisclosed cancer symptoms. Not only but also, HOOK will also develop cures for Hepatitis B and HIV with Gilead. The company has its base in New York, United States of America (USA).

  • Ocugen, Inc. (OCGN) stock gained 28.03% in the after-market. Here’s why

    The stock of Ocugen Inc (OCGN) closed the recent trading session at $3.46, losing 1.14% from the previous trading session. During the last check, the stock of OCGN gained 28.03% to $4.43, in the after-market. The gain came after the announcement made by the company about releasing their financial results for the fourth quarter of the fiscal year 2021. OCGN also announced that the FDA has lifted the clinical hold on the company’s investigational new drug.

    OCGN News

    On February 18, 2022, Ocugen Inc (OCGN) made an announcement regarding the release of its financial results for the fourth quarter of the fiscal year 2022. The company said that it will host a conference call at 8:30 am E.T on February 25, 2022. OCGN will also announce the pre-market earnings on the same day.

    Moreover, OCGN also announced the lifting of a clinical hold on the company’s IND by the FDA. The investigational new drug will help in evaluating the COVID-19 vaccine, BBV152, also known as COVAXIN.  COVAXIN is a COVID-19 investigational vaccine that utilizes the equivalent Vero cell. Vero cell is helpful in the development of polio antibodies.

    CEO Remarks

    The CEO of Ocugen Inc (OCGN), Shankar Musunuri, said that they are satisfied to have the option to push forward their clinical program for COVAXIN. He further added that he trusts this clinical program will carry them closer to an alternative COVID-19 vaccine.

    Moreover, Mr. Musunuri said that managing this pandemic requires more than one vaccine. They are cheered to have this option to keep fostering their vaccine.

    About OCGN

    Ocugen, Inc. is a clinical-stage biopharmaceutical organization that focuses on finding, developing, and commercializing quality treatments to fix visual deficiency illnesses. The company also focuses on fostering an antibody vaccine to save lives from COVID-19. OCGN is developing COVAXIN in US and Canadian markets with the help of Bharat Biotech. Ocugen have its headquarter in Malvem, Pennsylvania, United States of America (USA).

  • Energy Vault Holdings, Inc. (NRGV) stock gained 30.63% in the pre-market. Here’s why

    Energy Vault Holdings, Inc. (NRGV) stock gained 30.63% in the pre-market. Here’s why

    The stock of Energy Vault Holdings Inc (NRGV) closed the recent trading session at $11.1, gaining 13.61% from the previous trading session. The stock kept oscillating between $9.95 and $13.70. During the last check, the stock of NRGV rose in the pre-market, gaining 30.63%. On February 16, 2022, the company filed the form SC 13D with the SEC. The form refers to the statement of beneficial ownership of the securities.

    News

    On February 14, 2022, announced the beginning of trade on the New York stock exchange (NYSE) was. Energy Vault started trading under the ticker symbol of “NRGV”. The company also completed its business combination with Novus Capital Corporation II. Also, Energy Vault Holdings Inc declared Series C of $107M and a $50M license charge from Atlas Renewable to support the execution of its development strategy. The exchange will bring around $235 million in gross returns.

    The CEO of Energy Vault Holdings (NRGV), Robert Piconi, said that they are thrilled to start this new chapter as Energy Vault converts into a public company. He further added that the strategic partnership provides them with an opportunity to increase shareholders’ value. These partnerships will also allow them to execute their growth strategy.

    Moreover, Mr. Piconi concluded that he would like to thank all the employees, partners, and investors for believing in the company.

    About NRGV

    Energy Vault (NRGV) is a worldwide energy storage organization having expertise in gravity and kinetic energy. Energy Vault’s essential product is a gravity battery utilizing a multi-headed crane. The crane is used in storing energy by stacking weighty blocks made of composite material into a pinnacle. NRGV works on the mission to speed up the decarbonization of the planet by presenting the most manageable and efficient energy storage mechanics. Further, NRGV has a market capitalization of $1.48 billion. The company has its headquarter in Lugano, Switzerland.

  • Dropbox, Inc. (DBX) stock is losing in after-hours. Here’s why

    Dropbox, Inc. (DBX) stock is losing in after-hours. Here’s why

    The stock of Dropbox Inc (DBX) closed the recent trading session at $23.58, losing 5.3% from the previous trading session. DBX stock further declined in the after-market, losing 5.43%. The decline in the stock of Dropbox came after the announcement of quarterly results for the fiscal year 2021. The company also filed forms 8-K and 4 with the SEC. These forms refer to the reporting of quarterly results and changes in the beneficial ownership of securities, respectively.

    DBX Financials

    On February 17, 2022, Dropbox reported the financial results for the fourth quarter of the fiscal year 2021, which ended on December 31, 2021. DBX announced the revenue of the company to be $565.5 million in Q4 of FY21 versus $504.1 million in the same quarter of FY20. This marks an increase of 12.1% in revenue. Gross profit was $449.7 million in Q4 of FY21 as compared to $398.3 million in Q4 of FY20. The gross profit increased by 12.9%. Net income was $124.6 million in Q4 of FY21 versus a net loss of $345.8 million in the year-ago quarter. Diluted earnings per share for Q4 of the fiscal year 2021 was $0.32 as compared to the loss per share of $0.84 in the same quarter last year.

    Moreover, On February 11, 2022, DBX repurchased $1.2 billion of its common shares. The repurchase was authorized by the Board of Directors.

    CEO Remarks

    The CEO of Dropbox Inc (DBX), Drew Houston, said that the financial year of 2021 was a solid year for the company. He further said that he is proud of the work that their team has done during the first year as a Virtual First Company.

    Finally, Mr. Houston concluded that DBX is looking forward to 2022. They are invigorated regarding the opportunity they have to assist their clients and convey growth to their investors.

    About Dropbox

    Dropbox (DBX) is a document facilitating company that offers distributed cloud storage, record synchronization, individual cloud, and client programming. DBX has its headquarter in San Francisco, California, United States of America (USA).